What is it?
Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology, and Innovation) is a ₹10,000 crore, five-year initiative announced in the Union Budget 2026. It is designed to strengthen India’s biotechnology ecosystem and position the country as a global manufacturing hub for biologics and biosimilars.
Core objective:
Shift India from volume-based leadership in generic medicines to value-based leadership in high-value biopharmaceuticals, vaccines, and next-generation therapies.
Infrastructure & R&D Boost:
Establishment of 3 new National Institutes of Pharmaceutical Education and Research (NIPERs) and upgradation of 7 existing NIPERs to strengthen innovation capacity and skilled workforce development.
Clinical Trial Expansion:
Creation of a nationwide network of 1,000+ accredited clinical trial sites to accelerate drug development and global competitiveness.
Strategic Vision:
Reduce import dependency and strategically prepare for upcoming patent expiries of major global biologics.
With this structured push toward innovation and self-reliance, is India preparing to redefine its role in the global biopharma landscape?